Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Cilgavimab/Tixagevimab · AZD7442, AZD-8895

Monoclonal antibody · Antagonist of SARS-CoV-2 spike protein · developed by AstraZeneca

Phase 2/3 Most advanced trial (none active)
2 Registered trials

What is Cilgavimab/Tixagevimab?

Cilgavimab/Tixagevimab is a combination of two neutralizing human monoclonal antibodies, cilgavimab and tixagevimab, that bind the SARS-CoV-2 spike (S) protein and block viral attachment and entry into human cells. It is studied in COVID-19 for passive immunization.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as
AZD7442, AZD-8895
Drug type
Monoclonal antibody
Targets
SARS-CoV-2 spike protein
Mechanism
Antagonist of SARS-CoV-2 spike protein
Pathways
viral attachment and entry into human cells
Therapy area
Infectious disease
Developer
AstraZeneca
In trials of
SABS, VIR
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 2/3
UNII
F0LZ415Z3B

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT04518410 Phase 2/3 Coronavirus Completed SABS
NCT04501978 Phase 3 Covid19 Completed VIR

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

CoronavirusCovid19

Sources

Updated Nov 1, 2026.

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.